DOCSLIB.ORG

PROCESSING and CHARACTERIZATION of POLYMER MICROPARTICLES for CONTROLLED DRUG DELIVERY SYSTEMS DISSERTATION Presented in Partial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PROCESSING and CHARACTERIZATION of POLYMER MICROPARTICLES for CONTROLLED DRUG DELIVERY SYSTEMS DISSERTATION Presented in Partial PROCESSING AND CHARACTERIZATION OF POLYMER MICROPARTICLES FOR CONTROLLED DRUG DELIVERY SYSTEMS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the Graduate School of The Ohio State University By Aravind Chakrapani, M.S. The Ohio State University 2006 Doctor’s Examination Committee: Professor Derek J. Hansford, Advisor Professor William E. Carson Approved by Professor James T. Dalton Advisor Biomedical Engineering Graduate Program ABSTRACT We report a novel soft lithography based technique to fabricate non-spherical biodegradable polymeric microparticles of different sizes and shapes as drug delivery systems. Geometrical control over the shape and size of these microparticles renders them different aerodynamic and fluidic dynamic properties when compared to conventional spherical microparticles and may prove to be beneficial in certain drug delivery strategies, such as pulmonary and intravenous routes. The surface morphology of the particles was studied using a scanning electron microscope and size distribution of the particles was determined using a Coulter counter. The process is reproducible and millions of uniform biodegradable particles of various sizes and shapes with dimensions ranging from 2-30 µm have been fabricated and were collected by a simple vacuum filtration apparatus. In addition, we demonstrated encapsulation of a model drug (FITC), and FITC distributions within the particles were studied by confocal microscopy. Particle size is a critical parameter for several aspects of controlled drug delivery including control of drug-release kinetics, passive targeting to specific cell or tissue types, biodistribution upon administration and available routes of administration. In conclusion, the uniform, biodegradable polymeric microparticles produced have potential to be used in a variety of drug delivery applications and polymer-based microfabrication technology holds promise to produce sophisticated, multi-functional drug delivery devices. ii Dedicated to my loving parents and my sister iii ACKNOWLEDGMENTS First and foremost, I would like to thank my advisor Dr. Derek Hansford. No words can do justice to the gratitude I feel for the constant support, encouragement and guidance he provided throughout the course of my graduate studies. He has not only been an advisor but has also been a great friend and mentor over the last few years. Although my life in graduate school is coming to an end and I am looking forward to the next stage of my career, I will forever cherish the memories of my life in graduate school and hope to be in touch with Dr. Hansford for a long time. I would like to thank Dr. James Dalton for being part of my candidacy and graduate committee and for his valuable suggestion towards the project. I would like to thank Dr. William Carson for being part of my graduation committee and for having provided the use of his facilities and expertise. He got me in touch with Dr. Lesinski, who helped me with encapsulation experiments and patiently explained a lot of simple questions that I asked him about immunoassays. Needless to say, I am thankful to Dr. Lesinski for his help. I would like to thank all the members of my research group for their suggestions with my work and for being such great friends. In particular, I would like to thank Nick Ferrell, Jingjiao Guan for taking the time to answer a lot of my questions pertaining to research. Without their help my research work would not have been possible. I wish them all the best of luck in their endeavors. iv I would like to express my appreciation and gratitude to Melanie Senitko, Kirsten Gibbons, Vlad Marukhlenko, Ed Herderick and David Morelli at the biomedical engineering center. I would also extend my thanks to Dr. Ruegsegger and Dr. Moldovan. They have provided me constant support and encouragement with my academic work and helped create a great atmosphere at work. I wish to thank Derek Ditmer at MicroMD lab for his patience in training me on a lot of equipments at MicroMD and for being a good friend. I would also like to thank Jeremy Gaumer at Material Science engineering and Brian Kemmenoe for their patience and having me trained on the optical profilometer and confocal microscope, respectively. I am extremely grateful to all of my friends, for without their support, I would not have been able to work here 9000 miles away from home. It would not be possible for me to list all of their names and the memories they have provided over the last few years in the acknowledgments but I would have to at least mention the following: Amresh, Balaji, Guru, Hassan, Jingjiao, Manmohan, Nishat, Nick, Pradeep, Ramesh, Rangarajan, Senthil, Vinod, and Vyas. I express my sincere thanks to them for being such true friends, whom I could always count on. Finally, I would like to thank my parents and my sister for their unconditional love and encouragement throughout my life. Without their sacrifices and prayers, I would not have had the opportunity to pursue my dreams. Thank you so much! v VITA April 23, 1978…………………Born----Chennai, Tamilnadu, India 1999…………………………... B.Tech. Chemical Engineering, University of Madras, Tamilnadu, India 2003…………………………..M.S. Biomedical Engineering, The Ohio State University Columbus, Ohio, USA 2003-present………………….Graduate Associate, The Ohio State University, Columbus, Ohio, USA PUBLICATIONS Research Publications 1. Guan, J., A. Chakrapani, and D.J. Hansford, Polymer Microparticles Fabricated by Soft Lithography. Chemistry of Materials, 2005. 17(25): p. 6227- 6229. FIELDS OF STUDY Major Field: Biomedical Engineering vi TABLE OF CONTENTS Page Abstract……………………………………………………………………………………ii Acknowledgments………………………………………………………………………..iv Vita…………………………………………………………………………………….….vi List of Tables………………………………………………………………………….…xii List of Figures………………………………………………………………………...…xiii Chapters: 1. Introduction…………………………………………………………………………….1 2. Microparticles as Drug Delivery Systems……………………………………………...4 2.1. Biodegradable polymers for drug delivery systems………………………………..6 2.1.1. Properties of PLGA……………………………………………………………7 2.2. Fabrication techniques of biodegradable micro/nanoparticles for drug delivery…………………………………………………..9 2.2.1. Solvent evaporation and extraction based processes………………….............10 2.2.1.1. Single emulsion process…………………………………………………...10 vii 2.2.1.2. Double emulsion process…………………………………………….........13 2.2.2. Phase separation……………………………………………………………….15 2.2.3. Spray drying…………………………………………………………………...17 2.2.4. Microfabrication based drug delivery systems………………………………..18 2.2.4.1. Transdermal drug delivery systems……………………………………….20 2.2.4.2. Oral delivery………………………………………………………………24 2.2.4.3. Intravenous delivery………………………………………………………25 2.2.4.4. Microfabricated implants………………………………………………….26 2.2.4.5. Soft lithography…………………………………………………………...27 2.3. Practical examples………………………………………………………………...28 2.4. Summary...………………………………………………………………………...31 3. Fabrication of Biodegradable Polymeric Microparticles Using a Heat Press………....32 3.1. Photolithography…………………………………………………………………..33 3.2. PDMS stamp preparation………………………………………………………….33 3.3. Experimental methods…………………………………………………………….37 3.3.1. Materials…………………………………………………………………….37 3.3.2. Process overview……………………………………………………………37 3.3.3. Experimental set-up…………………………………………………………40 3.3.4. Fabrication process………………………………………………………….41 viii 3.4. Results and Discussion………………..…………………………………………..43 3.4.1. Coulter method of counting and sizing………………………………………47 3.4.2. Statistical analysis…………………………………………………………....49 3.5. Summary…………………………………………………………………………..49 4. Key Parameters and Process Improvements in Microtransfer Molding………………51 4.1. Introduction………………………………………………………………………..51 4.1.1Molds………………………………………………………………………...51 4.1.2. Spin-coating…………………………..…………………………………….52 4.1.3. Polymer solution…………………………………………………………....54 4.1.4. First stamp……………………..……………………………………………55 4.1.5. Uniform temperature and pressure……………………………………….....56 4.2. Summary...…………………………………………………………………………56 5. Fabrication of Polymeric Microparticles Using the Hot Embosser as a Stamping Device………………………………………………58 5.1. Experimental methods…………………………………………………………….60 5.1.1. Materials…………………………………………………………………….60 5.1.2. Photolithography…………………………………………………………….60 5.1.2. PDMS stamp preparation…………………………………………………....61 ix 5.1.4. Preparation of PLGA microparticles………………………………………..62 5.1.5. Characterization……………………………………………………………..62 5.2. Results and Discussion…………………...……………………………………….63 5.2.1. PDMS stamps……………………………………………………………….63 5.2.2. PLGA microparticles………………………………………………………..64 5.2.3. Statistical Analysis…………………………………………………………..69 5.3. Summary…………………………………………………………………………..71 6. Polymeric Microparticles as Drug Delivery Devices…………………………………73 6.1. Introduction………………………………………………………………………..73 6.2. Experimental methods………………………………………………………….…73 6.2.1. Encapsulation………………………………………………………………..73 6.2.2. Filtration……………………………………………………………………..74 6.2.3. Bi-layered particles………………………………………………………….74 6.2.4. Encapsulation of Taxol……………………………………………………...76 6.3. Results an Discussion….………………………………..………………………...76 6.4. Summary...………………………………………………………………………...82 7. Conclusions and Recommendations…………………………………………………..83 x 7.1. Conclusions……………………………………………………………………..…83 7.2. Recommendations……………………………………………………………...….84 References………………………………………………………………………………..86 xi LIST OF TABLES Table Page 2.1. Examples of pharmaceutical products based on drug loaded, biodegradable particles available on market…………………………25
Load more

Recommended publications
  • Approved Livestock Drug Registrations
    Livestock Drug Labels‐Approved and Provisional Status Firm: Product Name, Brand or Trademark Product Category Provisional ADEPTUS NUTRITION INC NIMBLE MEGA NUTRIENT (S&E RECEIVED) Physiological (Structure/Function) Provisional ADEPTUS NUTRITION INC NIMBLE ULTRA (S & E Received) Physiological (Structure/Function) Provisional ADEPTUS NUTRITION INC NIMBLE SUPREME (S & E Received) Physiological (Structure/Function) Approved ADEPTUS NUTRITION INC ADEPTUS WOUND AND SKIN SPRAY Topical Approved AFS DISTRIBUTING DURASOLE Topical Approved AGRI LABORATORIES LTD FERRRODEX 100 Injectable Approved AGRI LABORATORIES LTD VITAMIN E‐300 Injectable Approved AGRI LABORATORIES LTD PROPYLENE GLYCOL Physiological (Structure/Function) Approved AGRI LABORATORIES LTD IODINE WOUND SPRAY Topical Approved AGRI LABORATORIES LTD AGRI‐MECTIN (IVERMECTIN) INJECTION FOR CATTLE AND SWINE (RD) Restricted Drug‐/‐Wormer Approved AGRI LABORATORIES LTD AGRI‐MECTIN (IVERMECTIN) POUR‐ON FOR CATTLE (RD) Restricted Drug‐/‐Wormer Approved AGRI LABORATORIES LTD DEXTROSE 50% Injectable Approved AGRI LABORATORIES LTD PROHIBIT (LEVAMISOL HYDROCHLORIDE) SOLUBLE DRENCH POWDER (RD) Restricted Drug‐/‐Wormer Approved AGRI LABORATORIES LTD KAO‐PEC ANTI‐DIARRHEAL LIQUID Physiological (Structure/Function) Approved AGRI LABORATORIES LTD AGRIMYCIN 200 (OXYTETRACYCLINE) (CA RX RD) Restricted Drug‐/‐Injectable Approved AGRI LABORATORIES LTD VITAMIN E‐AD 300 INJECTABLE TOCOPHEROL WITH A+D Injectable Approved AGRI LABORATORIES LTD VITAMIN A D INJECTION Injectable Approved AGRI LABORATORIES LTD FORTIFIED
    [Show full text]
  • An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: a Review
    Muthadi Radhika Reddy /J. Pharm. Sci. & Res. Vol. 12(7), 2020, 925-940 An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: A Review Muthadi Radhika Reddy1* 1School of pharmacy, Gurunanak Institute of Technical Campus, Hyderabad, Telangana, India and Department of Pharmacy, Gandhi Institute of Technology and Management University, Vizag, Andhra Pradesh, India INTRODUCTION 2. Useful in situations where rapid onset of action Fast dissolving drug delivery systems were first developed required such as in motion sickness, allergic attack, in the late 1970s as an alternative to conventional dosage coughing or asthma forms. These systems consist of solid dosage forms that 3. Has wide range of applications in pharmaceuticals, Rx disintegrate and dissolve quickly in the oral cavity without Prescriptions and OTC medications for treating pain, the need of water [1]. Fast dissolving drug delivery cough/cold, gastro-esophageal reflux disease,erectile systems include orally disintegrating tablets (ODTs) and dysfunction, sleep disorders, dietary supplements, etc oral thin films (OTFs). The Centre for Drug Evaluation [4] and Research (CDER) defines ODTs as,“a solid dosage 4. No water is required for the administration and hence form containing medicinal substances which disintegrates suitable during travelling rapidly, usually within a matter of seconds, when placed 5. Some drugs are absorbed from the mouth, pharynx upon the tongue” [2]. USFDA defines OTFs as, “a thin, and esophagus as the saliva passes down into the flexible, non-friable polymeric film strip containing one or stomach, enhancing bioavailability of drugs more dispersed active pharmaceutical ingredients which is 6. May offer improved bioavailability for poorly water intended to be placed on the tongue for rapid soluble drugs by offering large surface area as it disintegration or dissolution in the saliva prior to disintegrates and dissolves rapidly swallowing for delivery into the gastrointestinal tract” [3].
    [Show full text]
  • Preparation and Characterization of Oil-In-Water and Water-In-Oil Emulsions
    1 Preparation and Characterization of Oil-in-Water and Water-in-Oil Emulsions Prepared For Dr. Reza Foudazi, Ph.D. Chemical and Materials Engineering New Mexico State University By Muchu Zhou May 10, 2016 2 1 Introduction 1.1 Purpose of This Report The objective of this report is to clarify what I have done this semester for research course CHME 498. The research interest is “Preparation and Characterization of Oil-in-Water and Water-in-Oil Emulsions”. Thus, I would like to talk about what is emulsion, what are the main characteristics of emulsions, what are the existing methods for preparations of emulsions and how to make simple emulsions. 1.2 Background of This Report Emulsion is a kind of mixture comprised of two or more liquids, which usually are immiscible, and surfactant. The common types of emulsions are oil-in-water emulsion and water-in-oil emulsion. According to Aronson (1988), the emulsions have important industrial value in the wide range of field and it has been studied extensively recently. The emulsions play an important role in the industrial production and it has been applied to many fields including food industry, cosmetics industry and pharmaceutical industry. In the food industry, emulsifier can function as dough conditioners in order to improve tolerance to variations in flour and other ingredient quality. In the cosmetic industry, the majority of facial creams and lotions are emulsions. 1.3 Scope of This Report 3 This report is going to cover the following contents. Introduction of emulsions. Effect of surfactant. Common materials for preparation of emulsions.
    [Show full text]
  • Tube Feeding Using the Bolus Method | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Tube Feeding Using the Bolus Method This information will help teach you how to use the bolus method to feed yourself and take your medications through your percutaneous endoscopic gastrostomy (PEG), gastrostomy tube (GT), or nasogastric tube (NGT). About Tube Feeding Tube feeding is when you get your nutrients through a feeding tube if you aren’t able to get enough through eating and drinking, or if you can’t swallow safely. Nutrients provide energy and help you heal. The bolus method is a type of feeding where a syringe is used to send formula through your feeding tube. The syringe you’ll use is called a catheter syringe. A catheter syringe doesn’t have a needle. It has a hole with a plunger in it. You draw up formula through the hole in the syringe then push the formula into your feeding tube with the plunger. A bolus refers to 1 “meal” of formula. You may have a feeding tube with a legacy connector or an ENFit connector. In this resource, we’ll show images of both types of connectors. For more information about your feeding tube, including how to manage side effects, read Tube Feeding Troubleshooting Guide. Tube Feeding Using the Bolus Method 1/11 Tube Feeding Guidelines Formula: __________ Total cans per day: ____________________ (8 ounces each) Calories per day: __________ You can choose the times of your feedings, as long as you reach your daily nutritional goals. Write in the times you prefer or your doctor, advanced practice provider (APP), or clinical dietitian nutritionist recommends.
    [Show full text]
  • Outpatient Parenteral Antimicrobial Therapy (OPAT) Self-Administration of Meropenem 500Mg IV Bolus
    Outpatient Parenteral Antimicrobial Therapy (OPAT) Self-administration of Meropenem 500mg IV bolus This leaflet is designed to support patients, and nursing staff who are teaching patients to self-administer Meropenem, with the assistance of the OPAT team. Please use this information in conjunction with the ‘Patient Self-Administration IV Therapy Competency Tool’. Through comprehensive individual demonstration, training and assessment, you will be able to: • Minimise the risk of introducing infection into a vein by keeping everything very clean. • Avoid touching the key parts of syringes, needles and extension sets. • Prevent injecting air into a vein by learning to prime syringes and extension sets carefully. What is Meropenem? Meropenem is an antibiotic; it is part of the antibiotic group carbapenem. Meropenem is given intravenously, by multiple doses throughout the day. Meropenem is only available as an injection. Please read the patient information leaflet inside medication box for further information about your medication. What you will need The ward nursing team and the OPAT nurses will ensure that you are happy and safe to administer Meropenem following the procedure below: Source: Outpatient Parenteral Antimicrobial Therapy Service Reference No: 6404-2 Issue date: 22/6/20 Review date: 22/6/23 Page no: 1 Equipment per 1 tray and sani-cloth detergent wipes dose: 1 pair sterile gloves and non-sterile gloves 3 10ml syringes 3 red needles 2 clinell wipes 2% 3 red bungs and sharps bin • 10ml ampoules 0.9% sodium chloride (normal saline) x2 Patient dose: 500mg • Meropenem 500mg vial and an ampoule of 10 mls water for injection What to do Remember to check the dose and the expiry date of the drug, diluent and normal saline.
    [Show full text]
  • New Pharmacological Treatments for Equine Reproductive Management
    New Pharmacological Treatments for Equine Reproductive Management P. J. Burns, Ph.D.11,2,3,4, D. L. Thompson, Jr, Ph.D.5, W. A. Storer Ph.D.5 R. Gilley B.S1,2,3., C. Morrow, D.V.M.3, J. Abraham, B. S. 7 & R. H. Douglas, Ph.D. 1,2,3 1BioRelease Technologies LLC, Birmingham, AL 2BET Pharm, Lexington, KY 3 Mt Laurel Veterinary Pharmacy, Birmingham, 4Burns BioSolutions INC, Lexington, KY 5Animal Sciences Department, Louisiana State University, Baton Rouge, LA 6 Mobile Veterinary Practice, Amarillo, Tx, 7 Abraham Equine, Mendota Ranch, Canadian,Tx Introduction Loy (1970) reported that only 55% of mares bred annually produce live foals. Recent data from The Jockey Club (2006) indicate that only 37,025 of 64,123 (57.7%) of thoroughbred mares bred during 2005 produced live foals. This is considerably lower than foaling rates of 71 to 85%, which are reported on farms where extensive reproductive management is used. Overall, reproductive management has not improved much in the last 30 years. The long estrus period, with ovulation at any time from 1 to 10 days after the beginning of estrus, has made reproductive management of cyclic mares time-consuming, expensive and most importantly, inefficient. Furthermore, the confusion associated with the long and variable transition from anestrous to cyclicity in mares greatly magnifies the complexity of efficient reproductive management for this category of mares. There is a need to develop and capitalize on controlled breeding programs for the horse industry based on new advances in the understanding of cost effective hormonal control of reproduction in mares and stallions.
    [Show full text]
  • Podder™ Resource Guide Omnipod DASH® System
    Podder™ Resource Guide Omnipod DASH® System Insulin Delivery That’s Simple, Smart, and Discreet Introduction | TABLE OF CONTENTS Get to Know the Omnipod DASH® System Introduction 04 Advanced Features 30 Welcome 04 Bolus 30 Supply List and Reorder 05 Basal 31 The Pod 06 Food Library 34 The Personal Diabetes Manager 07 Custom Foods 35 Basal/Bolus 10 Presets 36 Your Personal Diabetes Manager Settings 11 Counting Carbohydrates 12 Troubleshooting 39 Sick Day Management 39 Omnipod DASH® System Instructions 14 Hypoglycemia 40 How to Change the Pod 14 Hyperglycemia 42 Activate a New Pod 15 Notifications, Alerts & Alarms 44 Pod Placement/Prep/Tips 20 Blood Glucose Meter Pairing 22 Digital Resources 46 Blood Glucose Meter Syncing 23 Additional Notes 47 Delivering a Bolus 24 Suspend and Resume Insulin Delivery 25 Important Tips and Reminders 26 Additional Notes 29 Contact your local Omnipod® System representative or visit omnipod.com for more information. This Resource Guide is intended to be used in conjunction with your Diabetes Management Plan, input from your healthcare provider, and the Omnipod DASH® Insulin Management System User Guide. Personal Diabetes Manager imagery is for illustrative purposes only and should not be considered suggestions for user settings. Refer to the Omnipod DASH® Insulin Management System User Guide for complete information on how to use the Omnipod DASH® System, and for all related warnings and cautions. The Omnipod DASH® Insulin Management System User Guide is available online at omnipod.com or by calling Customer Care (24 hours/7 days), at 800-591-3455. CAUTION: Consult User Guide. This Resource Guide is for Personal Diabetes Manager model PDM-USA1-D001-MG-USA1.
    [Show full text]
  • Caregiver Guide
    INSULIN MANAGEMENT SYSTEM CAREGIVER GUIDE SIMPLE, NONSTOP INSULIN DELIVERY DESIGNED SO KIDS CAN BE KIDS 2 GET TO KNOW OMNIPOD.® WHAT’S DIFFERENT + The Pod . 2 ABOUT THE POD? SIMPLE. + The PDM (Personal Diabetes Manager) . .. 3 ® + How to check blood glucose and deliver a bolus . 4 OmniPod provides up to 3 days of nonstop insulin delivery* so kids with diabetes can run, play, and move, all while staying in control of their insulin . The system is simply 2 parts—the + How to change the Pod . 8 tubeless Pod and the handheld Personal Diabetes Manager (PDM) that your child keeps nearby Pod Placement Options . 10 so you can both wirelessly program insulin delivery . The Pod is waterproof †, lightweight, and Activate a New Pod . 11 discreet, and can be worn anywhere you would give an injection . OmniPod® helps simplify Step 1: Fill the Pod . 11 insulin delivery, so kids can be kids and you can worry less . That’s just part of what makes Step 2: Apply the Pod . 13 people so passionate about the Pod . Step 3: Press Start . 15 ® + How to enter a temporary basal rate . 16 Preparing your child to start on OmniPod . + How to suspend insulin delivery . 18 Whether you’re a school nurse, daycare provider, parent, grandparent, or other secondary + Supplies . 20 caregiver for a child using the OmniPod® Insulin Management System, this guide will lead you through some of the key functions you may need to perform . This guide is intended to be used in conjunction with the child’s Diabetes Management Plan, input from the parents and/or healthcare provider and the OmniPod® Insulin Management Have questions? System User Guide .
    [Show full text]
  • Int. J. Environ. Res. Public Health
    Int. J. Environ. Res. Public Health 2015, 12, 9988-10008; doi:10.3390/ijerph120809988 OPEN ACCESS International Journal of Environmental Research and Public Health ISSN 1660-4601 www.mdpi.com/journal/ijerph Review E-Cigarettes: A Review of New Trends in Cannabis Use Christian Giroud 1,2,3,*, Mariangela de Cesare 4, Aurélie Berthet 2,3,6, Vincent Varlet 1,2,3, Nicolas Concha-Lozano 2,3,6 and Bernard Favrat 2,3,5,7 1 Forensic Toxicology and Chemistry Unit, University Center of Legal Medicine (CURML), CH-1000 Lausanne 25, Switzerland; E-Mail: [email protected] 2 Department of Community Medicine and Health (DUMSC), Rue du Bugnon 44, CH-1011 Lausanne, Switzerland; E-Mails: [email protected] (A.B.); [email protected] (N.C.-L.); [email protected] (B.F.) 3 Lausanne University Hospital (CHUV), Rue du Bugnon 46, CH-1011, Lausanne, Switzerland 4 Unità di Medicina e Psicologia del Traffico, via Trevano 4, Casella postale 4044, CH-6904 Lugano, Switzerland; E-Mail: [email protected] 5 Unit of Traffic Medicine and Psychology, CURML, CH-1005 Lausanne, Switzerland 6 Institute for Work and Health (IST), Route de la Corniche 2, CH-1066 Epalinges - Lausanne, University of Lausanne and Geneva, Switzerland 7 Center of General Medicine, Department of Ambulatory Care and Community Medicine (PMU), University of Lausanne, Rue du Bugnon 44, CH-1011 Lausanne, Switzerland * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +41(0)-79-556-58-91; Fax: +41(0)-21-314-70-90. Academic Editor: Paul B.
    [Show full text]
  • Pharmacokinetics and Bioavailability of the Gnrh Analogs in the Form of Solution and Zn2+-Suspension After Single Subcutaneous Injection in Female Rats
    Eur J Drug Metab Pharmacokinet (2017) 42:251–259 DOI 10.1007/s13318-016-0342-5 ORIGINAL RESEARCH ARTICLE Pharmacokinetics and Bioavailability of the GnRH Analogs in the Form of Solution and Zn2+-Suspension After Single Subcutaneous Injection in Female Rats 1 2 3 Aleksandra Suszka-S´witek • Florian Ryszka • Barbara Dolin´ska • 4 5 1 1 Renata Dec • Alojzy Danch • Łukasz Filipczyk • Ryszard Wiaderkiewicz Published online: 14 May 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Follicle-stimulating hormone (FSH) and 17b-estradiol in the Background and Objectives Although many synthetic serum was measured by radioimmunological method. gonadoliberin analogs have been developed, only a few of Results The Extent of Biological Availability (EBA), calcu- them, including buserelin, were introduced into clinical lated on the base of AUC0-?, showed that in the form of practice. Dalarelin, which differs from buserelin by just solution buserelin and dalarelin display, respectively, only 13 one aminoacid in the position 6 (D-Ala), is not widely used and 8 % of biological availability of their suspension coun- so far. Gonadotropin-releasing hormone (GnRH) analogs terparts. Comparing both analogs, the EBA of dalarelin was are used to treat many different illnesses and are available half (53 %) that of buserelin delivered in the form of solution in different forms like solution for injection, nasal spray, and 83 % when they were delivered in the form of suspension. microspheres, etc. Unfortunately, none of the above drug The injection of buserelin or dalarelin, in the form of solution formulations can release the hormones for 24 h.
    [Show full text]
  • Grade 6 Science Mechanical Mixtures Suspensions
    Grade 6 Science Week of November 16 – November 20 Heterogeneous Mixtures Mechanical Mixtures Mechanical mixtures have two or more particle types that are not mixed evenly and can be seen as different kinds of matter in the mixture. Obvious examples of mechanical mixtures are chocolate chip cookies, granola and pepperoni pizza. Less obvious examples might be beach sand (various minerals, shells, bacteria, plankton, seaweed and much more) or concrete (sand gravel, cement, water). Mechanical mixtures are all around you all the time. Can you identify any more right now? Suspensions Suspensions are mixtures that have solid or liquid particles scattered around in a liquid or gas. Common examples of suspensions are raw milk, salad dressing, fresh squeezed orange juice and muddy water. If left undisturbed the solids or liquids that are in the suspension may settle out and form layers. You may have seen this layering in salad dressing that you need to shake up before using them. After a rain fall the more dense particles in a mud puddle may settle to the bottom. Milk that is fresh from the cow will naturally separate with the cream rising to the top. Homogenization breaks up the fat molecules of the cream into particles small enough to stay suspended and this stable mixture is now a colloid. We will look at colloids next. Solution, Suspension, and Colloid: https://youtu.be/XEAiLm2zuvc Colloids Colloids: https://youtu.be/MPortFIqgbo Colloids are two phase mixtures. Having two phases means colloids have particles of a solid, liquid or gas dispersed in a continuous phase of another solid, liquid, or gas.
    [Show full text]
  • The Paste Treatment of Inflammatory Skin Diseases, Especially of Eczema
    280 Progress of the Medical Sciences. [July The Paste Treatment of Inflammatory Skin Diseases, especially of Eczema. Dr. P. G. Unna, who has been largely instrumental in bringing into use the method of treating diseases of the skin by means of impermeable pastes, has recently given in the Monatshefte fur praktische Dermatologie, Nos. 2 and 3, 1884, a very complete list of the preparations used in his practice. Bolus Pastes (Bole Armeniac).—This is made of bolus alba (or clean kaolin) with vaseline and glycerine, in equal parts, or with olive, almond, or linseed oil, in the proportion of two to one, as B.—Boli alb®, parts 2 ; linseed oil, part 1.— M. The addition of more oil makes a liniment. In order to obtain a good paste for eczema it is necessary to add some liquor plumb, subacet. (or liquor alum, acet.) or oxide of zinc. jR.—Boli alba.', 5 parts; linseed oil, 3 parts; liquor plumb, acet., 2 parts.—M. This proportion is easily handled. It should be remembered that the bolus and oil are always to be mixed first, before the lead or aluminium is added, since the bolus and alum make an insoluble mass. In¬ stead of 5 parts of bolus, we may use 3 parts, and 2 of zinc oxide, as R.—Boli alb®, linseed oil (or glycerine), aa 30 parts; oxide of zinc and liq. plumb, subacet. aa 20 parts.—M. Make a paste. This is an excellent application for eczema. Instead of bolus earth, kaolin may be used, and instead of the bolus alba, the flava or the rubra may be used on the hands and face.
    [Show full text]